



(12) Translation of
European patent specification

(11) NO/EP 2925324 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/495 (2006.01)
A61P 25/18 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.03.29
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.12.30
(86)	European Application Nr.	13805597.5
(86)	European Filing Date	2013.11.28
(87)	The European Application's Publication Date	2015.10.07
(30)	Priority	2012.11.29, HU, P1200691
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(73)	Proprietor	Richter Gedeon Nyrt., Gyömrői út 19-21., 1103 Budapest, Ungarn
(72)	Inventor	PITTER, János György, Alsóerdősor u. 55/A., H-2030 Érd, Ungarn SZATMÁRI, Balázs, Sarlósfecske u. 21., H-1173 Budapest, Ungarn DEBELLE, Marc, Emilio Noelting 16A, F-68100 Mulhouse, Frankrike NÉMETH, György József, Hűvösvölgyi út 151/A., H-1021 Budapest, Ungarn LASZLOVSZKY, István, Bartók Béla út 16., H-1111 Budapest, Ungarn
(74)	Agent or Attorney	PLOUGMANN VINGTOFT, Postboks 1003 Sentrum, 0104 OSLO, Norge

(54)	Title	TRANS-4-2-[4-(2,3-DICHLOROPHENYL)-PIPERAZIN-1-YL]-ETHYL-N,N-DIMETHYLCARBAMOYL-CYCLOHEXYLAMINE FOR TREATING PRIMARY NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
(56)	References Cited:	WO-A1-2010/126527, WO-A1-2008/142462 KELLEY M E ET AL: "Empirical validation of primary negative symptoms: independence from effects of medication and psychosis.", THE AMERICAN JOURNAL OF PSYCHIATRY MAR 1999, vol. 156, no. 3, March 1999 (1999-03), pages 406-411, ISSN: 0002-953X CARPENTER W T JR ET AL: "Treatment of negative symptoms.", SCHIZOPHRENIA BULLETIN 1985, vol. 11, no. 3, 1985, pages 440-452, ISSN: 0586-7614 NÉMETH GYÖRGY ET AL: "Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial", THE LANCET, THE LANCET PUBLISHING GROUP, GB, vol. 389, no. 10074, 7 February 2017 (2017-02-07), pages 1103-1113, XP029946666, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(17)30060-0

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 1.** Trans-4-{2-[4-(2,3-diklorfenyl)-piperazin-1-yl]-etyl}-N,N-dimetylkarbamoyl-sykloheksylamin og/eller farmasøytisk akseptable salter og/eller hydrater og/eller solvater og/eller polymorfer derav for anvendelse ved behandling av primære negative symptomer på schizofreni.
- 2.** Trans-4-{2-[4-(2,3-diklorfenyl)-piperazin-1-yl]-etyl}-N,N-dimetylkarbamoyl-sykloheksylamin for anvendelse ifølge krav 1, i form av trans-4-{2-[4-(2,3-diklorfenyl)-piperazin-1-yl]-etyl}-N,N-dimetylkarbamoyl-sykloheksylaminhydroklorid og/eller hydrater og/eller solvater og/eller polymorfer derav.